Is Pulse Biosciences, Inc. (PLSE) overvalued or undervalued?
Updated Nov 10, 2026 · auto-modeled from live data · educational, not advice
Backup data source — This price comes from our backup market-data feed. Valuations here are built from company filings and are unaffected.
At a recent price of $58.17, Pulse Biosciences, Inc. (PLSE) trades 4274% above TickerWorth's base-case discounted-cash-flow (DCF) fair value of $1.33 per share — meaning the market currently prices PLSE overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -97.7% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
The valuation discounts Pulse Biosciences, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 12.6%, with a long-run terminal growth rate of 2.5%. About 63% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, PLSE's modeled DCF value ranges from about $1.33 to $1.33 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Pulse Biosciences, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of PLSE's intrinsic value. Figures update as new filings and prices come in.
The assumptions behind PLSE's DCF
| Input | Value | Source |
|---|---|---|
| Base-year revenue | $1,190,000 | Live feed — totalRevenue (TTM) |
| Base EBIT margin | 2.0% | Computed — trailing operatingMargins, held roughly flat |
| Forecast revenue growth | 5% → 5% → 4% → 4% → 4% | Assumption — TickerWorth's 5-year explicit forecast |
| Risk-free rate | 4.9% | Live feed — US 10-year Treasury yield (^TNX) |
| Beta | 1.64 | Live feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) |
| Terminal growth | 2.5% | Assumption — TickerWorth house default 2.5%, held below WACC |
| Diluted shares | 71M | Live feed — sharesOutstanding |
| Market price | $58.17 | Backup price feed · as of 2026-11-10 05:10 UTC |
Auto-modeled from live market data because it's frequently searched — this is NOT a hand-researched model. Every growth, margin and capital assumption is an algorithmic ESTIMATE, cached and refreshed periodically. Drag the WACC slider to test how sensitive the value is.
Explore more
Most undervalued stocks (per our valuation) · All valued stocks · Interactive PLSE valuation & downloadable modelEducational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is an educational DCF tool, not a licensed investment adviser. Figures are estimates derived from public filings and market data and can be wrong.